|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Aplastic anemia and severe pancytopenia during treatment with peg-interferon,ribavirin and telaprevir for chronic hepatitis C显示文摘Telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and ribavirin.Pancytopenia due to myelotoxicity caused by these drugs may occur,but severe hematological abnormalities or aplastic anemia(AA) have not been described.We collected all cases of severe pancytopenia observed during triple therapy with telaprevir in four Spanish centers since approval of the drug in 2011.Among 142 cirrhotic patients receiving treatment,7 cases of severe pancytopenia(5%) were identified and three were consistent with the diagnosis of AA.Mean age was 59 years,five patients had compensated cirrhosis and two patients had severe hepatitis C recurrence after liver transplantation.Severe pancytopenia was diagnosed a median of 10 wk after the initiation of therapy.Three patients had pre-treatment hematological abnormalities related to splenomegaly.In six patients,antiviral treatment was interrupted at the onset of hematological abnormalities.Two patients died due to septic complications and one patient due to acute alveolar hemorrhage.The remaining patients recovered.Severe pancytopenia and especially AA,are not rare during triple therapy with telaprevir in patients with advanced liver disease.Close monitoring is imperative in this setting to promptly detect serious hematological disorders and to prevent further complications. | Sabela Lens Jose L Calleja Ana Campillo Jose A Carrion Teresa Broquetas Christie Perello Juan de la Revilla Zoe Marino Maria-Carlota Londono Jose M Sanchez-Tapias Alvaro Urbano-Ispizua Xavier Forns | 2015 | World Journal of Gastroenterology2015，21，17： | 4 |
| 2 | Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant‐based cleansers显示文摘 | Zoe Draelos Sidney Hornby Russel M Walters Yohini Appa | 2013 | J Cosmet Dermatol2013，，4： | 1 |
| 3 | Therapeutic use of melatonin in schizophrenia:A systematic review显示文摘BACKGROUND Sleep dysfunction is a common problem in people with schizophrenia,and side effects of treatment often exacerbate metabolic and cardiovascular risk and may induce extrapyramidal side effects.Melatonin(N-acetyl-5-methoxytryptamine)is an endogenously produced hormone which has demonstrated direct and indirect antioxidant and neuroprotective effects.Previous studies have explored the use of exogenous melatonin in improving sleep outcomes in the general population,yet indications for use in schizophrenia are unclear.AIM To synthesize the evidence from clinical trials investigating prescribed melatonin as an adjunctive therapy in patients with schizophrenia.METHODS A systematic literature review of MEDLINE(Ovid),Embase,PsychINFO,and PubMed on the 27/08/20;and CINAHL and Cochrane Library databases,was conducted.Inclusion criteria were:a peer-reviewed clinical trial published in English;included a group of patients with schizophrenia;used melatonin as an adjunctive therapy;and reported any outcome of any duration.Exclusion criteria were:neurodegenerative diseases,primary sleep disorders,co-morbid substance use or animal studies.RESULTS Fifteen studies were included in the current review with the following primary outcomes:sleep(n=6),metabolic profile(n=3),tardive dyskinesia(n=3),cognitive function(n=2)and benzodiazepine discontinuation(n=1).CONCLUSION Adjunctive melatonin therapy has some positive outcomes for sleep,metabolic profile and tardive dyskinesia in patients with schizophrenia.No beneficial effect of melatonin was observed on outcomes of cognition or benzodiazepine discontinuation.Future studies utilizing larger samples and investigations specifically comparing the effect of melatonin as adjunctive therapy with different antipsychotics in patients with schizophrenia are required. | Cathy Duan Zoe M Jenkins David Castle | 2021 | World Journal of Psychiatry2021，11，8： | 1 |
| 4 | Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke显示文摘Background Alteplase improves functional outcomes of patients with acute ischaemic stroke,but its effects on symptomatic infarct swelling,an adverse complication of stroke and the influence of CT hyperdense artery sign(HAS)are unclear.This substudy of the Third International Stroke Trial aimed to investigate the association between HAS and symptomatic infarct swelling and effect of intravenous alteplase on this association.Methods We included stroke patients whose prerandomisation scan was non-contrast CT.Raters,masked to clinical information,assessed baseline(prerandomisation)and follow-up(24-48 hours postrandomisation)CT scans for HAS,defined as an intracranial artery appearing denser than contralateral arteries.Symptomatic infarct swelling was defined as clinically significant neurological deterioration≤7 days after stroke with radiological evidence of midline shift,effacement of basal cisterns or uncal herniation.Results Among 2961 patients,HAS presence at baseline was associated with higher risk of symptomatic infarct swelling(OR 2.21;95% CI 1.42 to 3.44).Alteplase increased the risk of swelling(OR 1.69;95% CI 1.11 to 2.57),with no difference between patients with and those without baseline HAS(p=0.49).In patients with baseline HAS,alteplase reduced the proportion with HAS at follow-up(OR 0.67;95% CI 0.50 to 0.91),where HAS disappearance was associated with reduced risk of swelling(OR 0.25,95% CI 0.14 to 0.47).Conclusion Although alteplase was associated with increased risk of symptomatic infarct swelling in patients with or without baseline HAS,it was also associated with accelerated clearance of HAS,which in return reduced swelling,providing further mechanistic insights to underpin the benefits of alteplase. | Simiao Wu Grant Mair Geoff Cohen Zoe Morris Anders von Heijne Nick Bradey Lesley Cala Andre Peeters Andrew J Farrall Alessandro Adami Gillian Potter Ming Liu Richard I Lindley Peter A G Sandercock Joanna M Wardlaw the IST-3 Collaborative Group | 2021 | Stroke & Vascular Neurology2021，6，2： | 1 |
| 5 | Duloxetin, a serotonin and noradrenaline reuptake inhibitor(SNRI) for the treatment ofstress urinary incontinence : A systematic review 显示文摘 | Paramananthan M Ammar A Zoe B | 2007 | Eur Urolocy2007，51，1： | 1 |
| 6 | Going to scale with professional skilled care显示文摘 | Marge K Zoe M Julia H | 2006 | Lancet2006，368，9544： | 1 |
| 7 | AFRI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a pro- spective study显示文摘 | Gorzalo C Guillermo FV Zoe M | 2012 | J Hepatol2012，57，2： | 1 |
| 8 | The Arabidopsis MALE STERILITY1(MS1) gene is a transcriptional regulator of male gametogenesis,with homology to the PHD-finger family of transcription factors显示文摘 | Wilson S M Morroll J D | 2001 | Plant J2001，28，： | 1 |
| 9 | The phase 2b HVTN 503/Phambili study test-of-concept HIV vaccine study, investigating a recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblind- ed, long-term follow-up显示文摘 | Glenda E Gray Zoe Moodie Barbara Metch M S | 2014 | Lancet Infect Dis2014，14，5： | 1 |
| 10 | The Arabidopsis MALE STERILITYI (MS) gene is a transcriptional regulator of male gametogenesis,with homology to the PHD-finger family of transcription factors显示文摘 | Y Zoe A Wilson S M Morroll J D | 2001 | Plant J2001，28，： | 1 |
| 11 | MR imaging findings in transient osteoporosis of the hip 显示文摘 | Konstantinos M Aristidis Z Zoe D | 2004 | EJR2004，50，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员